Inflation in the prices of major inputs and escalating interest expenses might continue to raise the company's aggregate costs, in turn, hurting its near-term profitability. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. The Zacks analyst thinks that escalating costs have become a major cause of concern for the company.